Nektar and Baxter to Develop PEGylated Therapeutics for Hemophilia

January 9, 2008
BioPharm International Editors

Nektar Therapeutics (San Carlos, CA) will work with subsidiaries of Baxter International, Inc. (Deerfield, IL), to develop new PEGylated therapeutics for hemophilia.

Nektar Therapeutics (San Carlos, CA), will work with subsidiaries of Baxter International, Inc. (Deerfield, IL), to develop new PEGylated therapeutics for hemophilia. The program will begin preclinical development in 2008.

Under the terms of the agreement, Nektar will receive up to $44 million in upfront and milestone payments, funding of research and development, and manufacturing revenues during research, clinical development, and commercialization. Nektar will also receive royalties on end product sales.

Baxter will be responsible for the development and commercialization of the product and Nektar will be responsible for the technology development used in the product, including the provision of clinical and commercial PEG reagents.

Nektar releaseBaxter release

Related Content:

News